Drugs / LLX-424
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06932146 | Mar → Sep 2025 | urolithiasis | Lilac Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LLX-424 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06932146 ↗ |
| Action | Inhibit | “glycolate oxidase inhibitor LLX-424” NCT06932146 ↗ |
| Route | Oral | “Tablets for oral administration” NCT06932146 ↗ |